Cancer clinical trials in the region Occitanie

348 currently recruiting clinical trials

Looking for clinical trials?

Clinical trial search is a complex process, with countless criteria to consider. Our AI assistant navigates this complexity with precise, expert-level analysis of the most relevant trials based on your medical profile. Our database is fully up to date, so you see only actively recruiting sites. It's fast and easy:

Create your account
Copy-paste your latest medical report
Our AI-based assistant does the rest for you

Whether you are a patient or a doctor, create an account to find and apply for the most relevant clinical trials:

Create your account

Phase 1 / Phase 2 Lymphoma #NCT05607420 #2022-501607-27-00

Étude évaluant UCART20x22 dans le lymphome non hodgkinien à cellules B

Partie escalade de dose

B cell lymphoma Large B cell lymphoma Primary mediastinal lymphoma Mantel cell lymphoma Follicular lymphoma Marginal zone lymphoma MALT lymphoma Indolent transformed lymphoma None 2 3 or more Chemotherapy Monoclonal antibodies

Systemic Treatment-Naive Car-T

4 recruiting sites

Cellectis SA

Phase 1 / Phase 2 Lymphoma #NCT05607420 #2022-501607-27-00

Étude évaluant UCART20x22 dans le lymphome non hodgkinien à cellules B

Partie extension de dose

B cell lymphoma Large B cell lymphoma Follicular lymphoma Indolent transformed lymphoma None 2 3 or more Chemotherapy Monoclonal antibodies

Systemic Treatment-Naive Car-T

4 recruiting sites

Cellectis SA

Phase 1 / Phase 2 Lymphoma #NCT06090539

Étude visant à évaluer le BMS-986458 seul et en association avec des agents anti-lymphome dans les lymphomes non hodgkiniens récidivants/réfractaires

B cell lymphoma Large B cell lymphoma Follicular lymphoma Indolent transformed lymphoma None 2 3 or more

Systemic Treatment-Naive Car-T

7 recruiting sites

Bristol-Myers Squibb

Phase 1 / Phase 2 Breast cancer #NCT04626635 #2022-501234-37-00

[COMBINE-EGFR-1] Essai visant à déterminer la sécurité du REGN7075 et son efficacité en association avec le CEMIPLIMAB chez les participants adultes atteints de cancers avancés

Cohorte A

HER2 Negative HR Negative Locally Advanced Metastatic 1 2 3 or more

Systemic Treatment-Naive

13 recruiting sites

Regeneron Pharmaceuticals

Phase 1 / Phase 2 Colon cancer Rectal cancer #NCT06923761 #2023-504845-30-00

[EMITT-1] Essai de ciblage de l'immunopeptidome médié par ERAP - 1

Module 2 Partie D cancer colorectal pMMR/MSS

Locally Advanced Metastatic MSS/pMMR 1 2 3 or more

Systemic Treatment-Naive

7 recruiting sites

Grey Wolf Therapeutics

Phase 1 / Phase 2 Lung cancer #NCT06669117 #2024-512760-64-00

Essai FIH du VERT-002 chez des patients atteints de tumeurs solides localement avancées ou métastatiques présentant des altérations du gène MET

Parties 2a et 2b

NSCLC (Non-Small Cell Lung Cancer) Locally Advanced Metastatic MET 1 2 3 or more

Systemic Treatment-Naive

4 recruiting sites

Laboratoires Pierre Fabre

Phase 1 / Phase 2 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer #NCT06669117 #2024-512760-64-00

Essai FIH du VERT-002 chez des patients atteints de tumeurs solides localement avancées ou métastatiques présentant des altérations du gène MET

Partie 1 (Escalade de dose)